A Phase 3, 22-week, Multi-centre, Randomised Withdrawal Study of TD- 9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure
Public Engagement 0169, Theravance Biopharma has decided to terminate both the Study 0170 Randomized
Withdrawal Study and the 0171 Long Term Safety study. No new participants will be allowed to
enroll into the 0170 study or rollover into the 0171 study